Yana Pikman

The paper presents an unbiased surfaceome atlas of leukemic cell lines, identifying novel surface proteins and discordant gene expression patterns, with CD70 highlighted as a potential therapeutic target in AML.

This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.

This study identifies transcriptional signatures of steroid resistance and altered immune responses in poverty-exposed children with B-ALL using single-cell RNA sequencing.

This study identifies MECOM's role in blocking differentiation via CEBPA repression, showing that targeting this regulatory element can promote differentiation and reduce leukemia burden in AMLs.

This study compares nutrient levels in plasma and bone marrow of pediatric B-ALL patients, identifying metabolic differences between subtypes and highlighting unique metabolic features in B-ALL circulation.

The paper develops a structure-based tool to evaluate kinase mutations in cancer by aligning them with known activating mutations using structural and functional data.

This study evaluates RMC-7977, a RAS(ON) inhibitor, showing efficacy against RAS-driven resistance in AML and potential for combination therapies.

The paper identifies outlier RNA isoform expression as a method to detect clinically relevant genomic variants in B-ALL and other cancers with high sensitivity and specificity.